Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
NCT03349840 · Weill Cornell Medical College in Qatar · PHASE4 · terminated · last registry update 2020-06-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated by the IRB and the Institutional Official after the MOPH and WCMQ audits” | – | Registry record, Weill Cornell Medical College in Qatar |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-05-17Also stopped (terminated): Hennepin Healthcare Research Institute, Degludec + Standard long-acting (NCT03001323)
- 2021-05-11Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04880850)
- 2021-04-19Phase 3 first posted: Novo Nordisk A/S, insulin icodec + insulin degludec (NCT04848480)
- 2021-03-12Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Placebo insulin icodec (NCT04795531)
- 2021-03-08Results posted on the registry: Eli Lilly and Company, LY3209590 + Insulin Degludec (NCT03736785)
- 2021-02-25Phase 3 first posted: Novo Nordisk A/S, Insulin degludec + Insulin Icodec (NCT04770532)
- 2021-02-18Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin Glargine 100U/mL (NCT04760626)
- 2021-02-01Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Placebo (insulin 287) (NCT03751657)
- 2021-01-25Results posted on the registry: East Coast Institute for Research, a drug against INSR (NCT03495908)
- 2021-01-12Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin glargine (NCT03687827)
- 2021-01-08Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine U100 (NCT03922750)
- 2021-01-08Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin Glargine (NCT03951805)
- 2020-11-10Results posted on the registry: University of California, San Francisco, GLP1 receptor agonist + basal insulin (NCT02846233)
- 2020-10-19Phase 3 first posted: Novo Nordisk A/S, Faster aspart + Insulin aspart (NCT04588259)
- 2020-09-28Results posted on the registry: University of Guadalajara, Insulin Degludec + Insulin Glargine (NCT02680457)
- 2020-09-11Results posted on the registry: Northwestern University, NPH Insulin + glargine (NCT03511521)
- 2020-09-11Also stopped (terminated): Northwestern University, NPH Insulin + glargine (NCT03511521)
- 2020-07-08Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04460885)
- 2020-07-07Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT03172494)
- 2020-05-07Results posted on the registry: Emory University, Glargine U300 + Glargine U100 (NCT03013985)
- 2020-05-01Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03214367)
- 2020-04-09Results posted on the registry: HealthPartners Institute, Insulin glulisine + Placebo (NCT02503501)
- 2020-04-09Also stopped (terminated): HealthPartners Institute, Insulin glulisine + Placebo (NCT02503501)
- 2020-03-27Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03214380)
- 2020-03-19Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT03175120)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision